Quark Pharmaceuticals, Inc.
Records under this name other than patents Quark Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Quark Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,121,020 | Methods for treating eye disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,701,961 | Methods for treating eye disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,444,983 | Composition of ANTI-ENDO180 Antibodies and Methods of Use for the Treatment of Cancer and Fibrotic Diseases Formerly held In force · High confidence | In force | High confidence | |
| US 9,993,567 | Composition of ANTI-ENDO180 Antibodies and Methods of Use for the Treatment of Cancer and Fibrotic Diseases Formerly held In force · Low confidence | In force | Low confidence | |
| US 8,765,931 | A Double-Stranded Oligonucleotide Compound for Down-Regulating the Expression of CASP2 Gene Formerly held In force · High confidence | In force | High confidence | |
| US 8,901,097 | Methods for Delivery of Sirna to the Spinal Cord and Therapies Arising Therefrom Formerly held In force · High confidence | In force | High confidence | |
| US 10,195,145 | Method for Treating Fibrosis Using Sirna and a Retinoid-Lipid Drug Carrier Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,456,984 | Method for Treating Fibrosis Using Sirna and a Retinoid-Lipid Drug Carrier Formerly held In force · High confidence | In force | High confidence | |
| US 9,382,542 | Double-stranded RNA compounds to CASP2 and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,570,394 | Double-stranded RNA compounds to CASP2 and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record |